Clinical Trial Update: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating adjunctive everolimus (RAD-001) for epilepsy in children with Sturge-Weber syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sturge-weber Syndrome

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Sturge Weber Syndrome | Phase 2 | Status: WITHDRAWN